Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Approved FDF
Recipient : Coherus Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Accord BioPharma Announces Completion of UDENYCA Franchise Acquisition from Coherus
Details : Udenyca, a biosimilar to Neulasta (pegfilgrastim), expands the company's portfolio of FDA-approved products and accelerates Accord BioPharma's growth in the biosimilar industry.
Product Name : Udenyca
Product Type : Protein
Upfront Cash : Undisclosed
April 14, 2025
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Recipient : Coherus Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Accord BioPharma Gains FDA Approval of HERCESSI™ Biosimilar For Cancer
Details : Hercessi (trastuzumab-biosimilar) is biosimilar to Herceptin, which is indicatedfor the treatment of HER2 overexpressing breast cancer & metastatic gastric or gastroesophageal junction adenocarcinoma.
Product Name : Hercessi
Product Type : Antibody
Upfront Cash : Inapplicable
September 18, 2024
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Intas Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts BLA for Dong-A ST's DMB-3115, a Proposed Biosimilar to Stelara
Details : DMB-3115 (ustekinumab-biosimilar) is an IL-12/23 inhibitor which is being evaluated in phase 3 clinical trials for the treatment of patients with moderate-to-severe chronic plaque psoriasis.
Product Name : DMB-3115
Product Type : Antibody
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Intas Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Accord BioPharma’s HERCESSI™ (trastuzumab-strf) Approved as Herceptin® Biosimilar in U.S
Details : Hercessi (trastuzumab-biosimilar) is a HER2/neu receptor antagonist, which is indicated for HER2 overexpressing breast cancer & metastatic gastric or gastroesophageal junction adenocarcinoma.
Product Name : Hercessi
Product Type : Antibody
Upfront Cash : Inapplicable
April 29, 2024
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leuprolide Mesylate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Eversana
Deal Size : Undisclosed
Deal Type : Partnership
Accord Bio and EVERSANA Announce Partnership to Support the Launch of CAMCEVI
Details : CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide for subcutaneous injection that comes in a pre-filled syringe with no mixing required. In an open-label, single-arm study of 137 adults who received 42mg of CAMCEVI on Day 0 and ...
Product Name : Camcevi
Product Type : Hormone
Upfront Cash : Undisclosed
June 29, 2022
Lead Product(s) : Leuprolide Mesylate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Eversana
Deal Size : Undisclosed
Deal Type : Partnership